Heart Failure News and Research

RSS

Heart failure (HF) is a condition in which a problem with the structure or function of the heart impairs its ability to supply sufficient blood flow to meet the body's needs. It should not be confused with cardiac arrest or myocardial infarction.

Group of drugs used to treat heart failure shows promise for fighting colon cancer

Scientists in Sweden are reporting for the first time that a group of drugs used to treat heart failure shows promise for fighting colon cancer. The study is in ACS' Journal of Natural Products, a monthly publication. Colon cancer is the third most common cancer in the United States, with more than 150,000 cases diagnosed in the U.S. each year.

17 Dec 2009

Low plasma CETP activity associated with increased risk of heart disease, says study

Although seen as a potential heart disease therapy, raising high-density lipoprotein (HDL) cholesterol levels by inhibiting activity of a transfer protein may not be effective, a new study suggests.

16 Dec 2009

Enrolment for pivotal Phase II/III trial of C-Cure completed ahead of schedule

Cardio3 BioSciences, a leading Belgian biotechnology company specialising in cell-based therapies for the treatment of cardiovascular diseases, announced today that it has completed, two months ahead of schedule, enrolment in the first stage of its pivotal Phase II/III trial of C-Cure, a unique stem cell therapy for heart failure.

15 Dec 2009

Geron’s request for declaration of interference regarding Novocell' U.S. Patent No. 7,510,876 granted

Geron Corporation today announced that the U.S. Patent and Trademark Office, Board of Patent Appeals and Interferences, has granted Geron’s request to declare an interference between a patent application owned by Geron and U.S. Patent No. 7,510,876 (the ‘876 patent) owned by Novocell, Inc.

15 Dec 2009

Phase III clinical trial evaluating darusentan misses its co-primary efficacy endpoints

Gilead Sciences, Inc. today announced that DAR-312 (DORADO-AC), a Phase III clinical trial evaluating darusentan, the company’s endothelin receptor antagonist (ERA) for the treatment of resistant hypertension, did not achieve its co-primary efficacy endpoints of change from baseline to week 14 in trough sitting systolic blood pressure (SBP) and diastolic blood pressure (DBP) compared to placebo.

15 Dec 2009

MHI launches new research program in heart failure

The Montreal Heart Institute (MHI) and its Foundation (MHIF) launched today the Carolyn and Richard J. Renaud Research Chair in Heart Failure, the first of its kind in Québec.

14 Dec 2009

Genentech announces Phase III study of Avastin in women treated with chemotherapy for advanced breast cancer

Genentech, Inc., a wholly owned member of the Roche Group, today announced results from a Phase III study (RIBBON 2) of Avastin® (bevacizumab) in women who had previously been treated with initial (first-line) chemotherapy for advanced HER2-negative breast cancer and needed additional (second-line) treatment.

14 Dec 2009

Changes to NCQA's disease management Accreditation and Certification standards released

The National Committee for Quality Assurance (NCQA) today released changes to its disease management Accreditation and Certification requirements, adding voluntary performance reporting for five chronic conditions.

14 Dec 2009

Pfizer announces results from studies evaluating neratinib

Pfizer Inc. today announced results from studies evaluating neratinib (HKI-272), an investigational, orally administered, pan-ErbB inhibitor, in patients with human epidermal growth factor receptor-2 (HER2, also known as ErbB2) positive breast cancer at the 2009 CTRC-AACR San Antonio Breast Cancer Symposium (SABCS).

14 Dec 2009

Combination therapy improves overall survival in women with advanced breast cancer

In a clinical study, women with an aggressive form of breast cancer experienced a median survival of 14 months when treated with an investigational combination of TYKERB® (lapatinib) plus HERCEPTIN® (trastuzumab). The results of the Phase III study in HER2-positive metastatic breast cancer were presented during the 32nd Annual CTRC-AACR San Antonio Breast Cancer Symposium, held in San Antonio, Texas (Dec. 9 - 13).

14 Dec 2009

Study finds widespread variations in CRT use for patients with severe heart failure

Most patients with heart failure likely to benefit from a pacemaker including the capacity for cardiac resynchronization therapy (CRT) do not receive such an implantable device, reports a national study in the December 2009 issue of the American Heart Journal.

14 Dec 2009

VNA of Greater Philadelphia expands its home health and specialty services in Bucks County

The Visiting Nurse Association (VNA) of Greater Philadelphia is expanding its traditional home health and specialty services to patients who reside in lower Bucks County.

14 Dec 2009

Obese patients loosing moderate amount of weight improve their cardiovascular health, says study

Obese patients who lost a moderate amount of weight by eating less and exercising more improved their cardiovascular health, says a study at Washington University School of Medicine in St. Louis.

14 Dec 2009

Chemotherapy improves overall survival in postmenopausal breast cancer patients

Chemotherapy generally improves survival in postmenopausal breast cancer patients, according to a landmark study led by Dr. Kathy Albain of Loyola University Health System.

11 Dec 2009

Italy's economically disadvantaged people have higher rates of hospitalization for ACSC disorders

Despite free public healthcare, Italy's poor are more likely to end up in hospital with avoidable conditions, new research shows. This pattern, reported today in the online open access journal BMC Public Health, mirrors findings from a number of different healthcare systems around the world, although to date fewer studies have been completed in Europe.

11 Dec 2009

Tasigna demonstrates greater efficacy over Gleevec in chronic Ph+ CML patients

In a large Phase III clinical trial, Tasigna (nilotinib capsules) demonstrated greater efficacy over Gleevec (imatinib) in the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase. The new clinical data were just presented as a late breaking abstract at the 51st annual meeting of the American Society of Hematology (ASH), in New Orleans, Louisiana.

11 Dec 2009

Regulus Therapeutics to host educational webinar about microRNA biology

Regulus Therapeutics Inc., founded by Alnylam Pharmaceuticals, Inc., and Isis Pharmaceuticals, Inc., unveiled plans for an educational webinar about microRNA biology that will highlight several recent exciting discoveries in the field and showcase the therapeutic strategies based on microRNA.

10 Dec 2009

Cardiologists receive K23 research grant from NIH

Brian H. Annex, M.D., chief of the Division of Cardiovascular Medicine at the University of Virginia Health System, says he feels like the coach of a championship team. "Going three for three is truly extraordinary," he says with a mixture of pride and awe in his voice.

10 Dec 2009

New health study reveals Ontario women less likely to receive cardiac care than men

Gender differences persist in the quality of cardiac care across Ontario, according to a health study by researchers at St. Michael's Hospital and the Institute for Clinical Evaluative Sciences (ICES).

10 Dec 2009

Today's opinions and editorials

The language in our amendment is completely consistent with the Hyde Amendment, which in the 33 years since its passage has done nothing to inhibit private health insurers from offering abortion coverage. There is no reason to believe that a continuation of this policy would suddenly create undue hardship for the insurance industry — or for those who wish to use their private insurance to pay for an abortion (Rep. Bart Stupak, 12/8).

9 Dec 2009

Heart Failure News and Research

Further Reading

Group of drugs used to treat heart failure shows promise for fighting colon cancer

Low plasma CETP activity associated with increased risk of heart disease, says study

Enrolment for pivotal Phase II/III trial of C-Cure completed ahead of schedule

Geron’s request for declaration of interference regarding Novocell' U.S. Patent No. 7,510,876 granted

Phase III clinical trial evaluating darusentan misses its co-primary efficacy endpoints

MHI launches new research program in heart failure

Genentech announces Phase III study of Avastin in women treated with chemotherapy for advanced breast cancer

Changes to NCQA's disease management Accreditation and Certification standards released

Pfizer announces results from studies evaluating neratinib

Combination therapy improves overall survival in women with advanced breast cancer

Study finds widespread variations in CRT use for patients with severe heart failure

VNA of Greater Philadelphia expands its home health and specialty services in Bucks County

Obese patients loosing moderate amount of weight improve their cardiovascular health, says study

Chemotherapy improves overall survival in postmenopausal breast cancer patients

Italy's economically disadvantaged people have higher rates of hospitalization for ACSC disorders

Tasigna demonstrates greater efficacy over Gleevec in chronic Ph+ CML patients

Regulus Therapeutics to host educational webinar about microRNA biology

Cardiologists receive K23 research grant from NIH

New health study reveals Ontario women less likely to receive cardiac care than men

Today's opinions and editorials

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News